BPC August 05 update

​Bristol-Myers BMY patent win +5% AH; Horizon HZNP +24% on second quarter earnings

Price and Volume Movers

Bristol-Myers Squibb Company (NYSE:BMY) shares are trading up 5% after hours to $62.80, while Pfizer (NYSE:PFE) shares have added 2% to $39.18. The price action follows news that the companies won a court ruling upholding patents for their blood-thinner, Eliquis, with the ruling noting that generic drug manufacturer, Sigmapharm, would infringe the patents.

Novavax, Inc. (NASDAQ: NVAX) shares closed up 10% to $173.49 following news Tuesday of promising initial Phase 1 data from its trial of its COVID‑19 vaccine. JP Morgan raised its rating of the stock from Neutral to Overweight with a price target of $275.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced after hours that it intends to offer and sell common shares in an underwritten public offering.

Horizon Therapeutics plc (NASDAQ:HZNP) shares closed up 24% to $76.38 on the back of its second quarter earnings report. The company saw net sales rising 44% over the year to $463m, well above analyst expectations. The company followed up the news announcing after hours a public offering of $700m of its ordinary shares.

-

Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume:

ADVANCERS:

Biofrontera AG (BFRA): $26.80; +379%.

Aileron Therapeutics, Inc. (ALRN): $1.48; +35%.

Alimera Sciences, Inc. (ALIM): $6.98; +28%.

Iteos Therapeutics, Inc. (ITOS): $28.88; +17%.

Aerpio Pharmaceuticals, Inc. (ARPO): $1.51; +14%.

DECLINERS:

Alterity Therapeutics Limited (ATHE): $2.91; -15%.

Celsion Corporation (CLSN): $1.14; -10%.

Inozyme Pharma, Inc. (INZY): $22.43; -9%.

Can-Fite BioPharma Ltd. (CANF): $2.26; -9%.

Corcept Therapeutics Incorporated (CORT): $14.36; -8%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

ABIO – ARCA biopharma Inc.
Gencaro
Chronic Heart Failure

Phase 3 Phase 3 trial to be initiated in 2021 subject to financing.
$30.6 million

ACIU – AC Immune SA
Semorinemab (Anti-Tau RO7105705)
Alzheimer’s disease

Phase 2 Phase 2 top-line data due 2H 2020.
$644.2 million

ALNA – Allena Pharmaceuticals Inc.
Reloxaliase ALLN-177 (URIROX-2)
Enteric Hyperoxaluria

Phase 3 Phase 3 interim analysis due 1Q 2022 and top-line data 3Q 2022.
$52 million

BCLI – Brainstorm Cell Therapeutics Inc.
NurOwn
Amytrophic lateral sclerosis (ALS)

Phase 3 Phase 3 top-line data due by the end of November 2020.
$475.8 million

BLPH – Bellerophon Therapeutics Inc.
INOpulse delivery device
Pulmonary Hypertension associated with Pulmonary Fibrosis (PH-PF)

Phase 3 Phase 3 initiation due 2H 2020.
$100.4 million

CLVS – Clovis Oncology Inc.
Lucitanib with Opdivo (LIO-1)
Solid tumors

Phase 1/2 Phase 1b initial data presented at ESMO September 17, 2020. ORR 2/15. Phase 2 commencement of enrollment announced August 5, 2020.
$614.3 million

CRBP – Corbus Pharmaceuticals Holdings Inc.
Lenabasum (resunab) - DETERMINE
Dermatomyositis

Phase 3 Phase 3 data due 4Q 2021.
$155.3 million

GRTS – Gritstone Oncology Inc.
GRANITE-001 (GO-004)
Colorectal Cancer / Gastric Cancer

Phase 1/2 Phase 2 trial to commence 2H 2020 with data due 2H 2021. Additional Phase 1 data due 2H 2020.
$124.6 million

LYRA – Lyra Therapeutics Inc.
LYR-210 - LANTERN
Chronic rhinosinusitis / Chronic Sinusitis

Phase 2 Phase 2 data due 4Q 2020.
$154.2 million

PTCT – PTC Therapeutics Inc.
PTC-AADC
AADC deficiency

BLA Filing BLA filing due 2H 2020.
$3.2 billion

REGN – Regeneron Pharmaceuticals Inc.
REGN-COV2
COVID-19 (Anti-viral antibody)

Phase 2/3 Phase 2/3 trial has been initiated. Initial virology and biomarker data due September 2020.
$59.1 billion

TCON – TRACON Pharmaceuticals Inc.
Envafolimab
Sarcomas

Phase 3 Phase 3 trial to commence 4Q 2020 with interim data due 2021 and final data in 2022.
$83.1 million

VBIV – VBI Vaccines Inc.
VBI-2900
COVID-19 vaccine

Phase 1 Clinical trials to commence by the end of 2020.
$827.7 million

VNDA – Vanda Pharmaceuticals Inc.
Tradipitant
Gastroparesis

Phase 3 Phase 3 enrollment to be completed 1H 2021.
$538.3 million